Cargando…

Recall of substandard medicines in Brazil during the period 2010–2018

BACKGROUND: Even with all the care taken during the production process, the pharmaceutical industries are still subject to manufacturing medicines with quality deviations, generating commercialized products without the required quality and necessitating their subsequent recall from the market. The o...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Cristiani Lopes Capistrano Gonçalves, Machado, Virgínia Freire, de Freitas Tavares, Heitor, Ribeiro, Gabriel Lucas Marques, Arrais, Paulo Sérgio Dourado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007835/
https://www.ncbi.nlm.nih.gov/pubmed/36899376
http://dx.doi.org/10.1186/s12913-023-09225-w
_version_ 1784905617005084672
author Oliveira, Cristiani Lopes Capistrano Gonçalves
Machado, Virgínia Freire
de Freitas Tavares, Heitor
Ribeiro, Gabriel Lucas Marques
Arrais, Paulo Sérgio Dourado
author_facet Oliveira, Cristiani Lopes Capistrano Gonçalves
Machado, Virgínia Freire
de Freitas Tavares, Heitor
Ribeiro, Gabriel Lucas Marques
Arrais, Paulo Sérgio Dourado
author_sort Oliveira, Cristiani Lopes Capistrano Gonçalves
collection PubMed
description BACKGROUND: Even with all the care taken during the production process, the pharmaceutical industries are still subject to manufacturing medicines with quality deviations, generating commercialized products without the required quality and necessitating their subsequent recall from the market. The objective of this study was to evaluate the reasons that led to the recall of medicines in Brazil in the period evaluated. METHODS: This is a descriptive study (using document analysis), on the recall of substandard medicines registered on the website of the National Health Surveillance Agency (ANVISA), from 2010 to 2018. The variables studied were the type of medicine (reference, generic, similar, specific, biological, herbal, simplified notification, new and radiopharmaceutical), type of pharmaceutical dosage form (solid, liquid, semi-solid and parenteral preparation), and reason for recall (Good manufacturing practices, quality and quality/good manufacturing practices). RESULTS: A total of n = 3,056 recalls of substandard medicine were recorded. Similar medicines had a higher recall index (30.1%), followed by generics (21.3%), simplified notification (20.7%) and reference (12.2%). Different dosage forms had similar recalls: solids (35.2%), liquids (31.2%) and parenteral preparations (30.0%), with the exception of semi-solids (3.4%). The reasons for the highest occurrences were related to good manufacturing practices (58.4%) and quality (40.4%). CONCLUSION: The probable cause for this high number of recalls is the fact that, even with all the quality controls and processes in accordance with good manufacturing practices, errors can occur, both human and in automated processes, thus causing the release of batches that should not have been approved. In summary, it is necessary for manufacturers to implement a robust and well structured quality system in order to avoid such deviations, and it is up to ANVISA to apply greater oversight in the post marketing of these products.
format Online
Article
Text
id pubmed-10007835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100078352023-03-12 Recall of substandard medicines in Brazil during the period 2010–2018 Oliveira, Cristiani Lopes Capistrano Gonçalves Machado, Virgínia Freire de Freitas Tavares, Heitor Ribeiro, Gabriel Lucas Marques Arrais, Paulo Sérgio Dourado BMC Health Serv Res Research BACKGROUND: Even with all the care taken during the production process, the pharmaceutical industries are still subject to manufacturing medicines with quality deviations, generating commercialized products without the required quality and necessitating their subsequent recall from the market. The objective of this study was to evaluate the reasons that led to the recall of medicines in Brazil in the period evaluated. METHODS: This is a descriptive study (using document analysis), on the recall of substandard medicines registered on the website of the National Health Surveillance Agency (ANVISA), from 2010 to 2018. The variables studied were the type of medicine (reference, generic, similar, specific, biological, herbal, simplified notification, new and radiopharmaceutical), type of pharmaceutical dosage form (solid, liquid, semi-solid and parenteral preparation), and reason for recall (Good manufacturing practices, quality and quality/good manufacturing practices). RESULTS: A total of n = 3,056 recalls of substandard medicine were recorded. Similar medicines had a higher recall index (30.1%), followed by generics (21.3%), simplified notification (20.7%) and reference (12.2%). Different dosage forms had similar recalls: solids (35.2%), liquids (31.2%) and parenteral preparations (30.0%), with the exception of semi-solids (3.4%). The reasons for the highest occurrences were related to good manufacturing practices (58.4%) and quality (40.4%). CONCLUSION: The probable cause for this high number of recalls is the fact that, even with all the quality controls and processes in accordance with good manufacturing practices, errors can occur, both human and in automated processes, thus causing the release of batches that should not have been approved. In summary, it is necessary for manufacturers to implement a robust and well structured quality system in order to avoid such deviations, and it is up to ANVISA to apply greater oversight in the post marketing of these products. BioMed Central 2023-03-10 /pmc/articles/PMC10007835/ /pubmed/36899376 http://dx.doi.org/10.1186/s12913-023-09225-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Oliveira, Cristiani Lopes Capistrano Gonçalves
Machado, Virgínia Freire
de Freitas Tavares, Heitor
Ribeiro, Gabriel Lucas Marques
Arrais, Paulo Sérgio Dourado
Recall of substandard medicines in Brazil during the period 2010–2018
title Recall of substandard medicines in Brazil during the period 2010–2018
title_full Recall of substandard medicines in Brazil during the period 2010–2018
title_fullStr Recall of substandard medicines in Brazil during the period 2010–2018
title_full_unstemmed Recall of substandard medicines in Brazil during the period 2010–2018
title_short Recall of substandard medicines in Brazil during the period 2010–2018
title_sort recall of substandard medicines in brazil during the period 2010–2018
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007835/
https://www.ncbi.nlm.nih.gov/pubmed/36899376
http://dx.doi.org/10.1186/s12913-023-09225-w
work_keys_str_mv AT oliveiracristianilopescapistranogoncalves recallofsubstandardmedicinesinbrazilduringtheperiod20102018
AT machadovirginiafreire recallofsubstandardmedicinesinbrazilduringtheperiod20102018
AT defreitastavaresheitor recallofsubstandardmedicinesinbrazilduringtheperiod20102018
AT ribeirogabriellucasmarques recallofsubstandardmedicinesinbrazilduringtheperiod20102018
AT arraispaulosergiodourado recallofsubstandardmedicinesinbrazilduringtheperiod20102018